Kura reports Phase II data for tipifarnib in CMML

Kura Oncology Inc. (NASDAQ:KURA) reported preliminary data from nine evaluable patients with wild-type RAS chronic myelomonocytic leukemia (CMML) in a Phase II trial showing that

Read the full 259 word article

User Sign In